6,405
+1.03%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cosmos Pharmaceutical
Its shares trade on Tokyo Stock Exchange under the ticker 3349.T. It has been listed since 11 November 2004. In the fiscal year to 31 May 2026, it reported revenue of ¥1.10trn and net income of ¥32.05bn. At that date it held total assets of ¥596.49bn and shareholders' equity of ¥283.70bn.
COSMOS Pharmaceutical Corp. engages in the operation of drugstores. The company is headquartered in Fukuoka, Fukuoka-Ken. The company went IPO on 2004-11-11. The firm offers medical goods, including general self-medication products, tonic drinks, oral care products, nursing care products, vitamin supplements, health food products, diet food and dispensing. Cosmetic products include cosmetic products for women and men, hair care products and bath agents. Miscellaneous goods include baby goods, detergents, insecticides, deodorizers, bath goods, toiletries, cookware, gardening goods, automobile goods and clothing products. General food products include processed food products, daily food products, seasonings, confectionery, non-alcoholic beverages and alcoholic beverages. The company also provides tobacco and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Food & Staples Retailing
- Listed since
- 11 Nov 2004
- Employees
- 4,240
- Website
- cosmospc.co.jp ↗
Leadership
Pay as last reported
- Mr. Hideaki YokoyamaPresident, Representative Director, since 2016
- Mr. Futoshi ShibataDirector of Business Planning, Director, since 2012
- Mr. Yukitaka UnoDirector of Product Development, Director, since 2012
- Mr. Michiyoshi KosakaDirector
- Ms. Chiyoko HaradaIndependent Director
- Ms. Yuki WatabeIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 30
- Environment
- 26
- Social
- 25
- Governance
- 40
- Women in the workforce
- 84.82338%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cosmos Pharmaceutical Corp has established a strong market presence in the pharmaceutical industry, catering to a diverse range of medical needs.
- The company boasts a robust product portfolio, offering a wide range of quality medications and healthcare products.
- With advanced research and development capabilities, Cosmos continually introduces innovative solutions, gaining a competitive edge in the market.
- The company has a strong distribution network ensuring wide product availability and customer reach.
Weaknesses
- Cosmos Pharmaceutical Corp faces challenges related to maintaining regulatory compliance and adhering to changing government policies.
- The company may encounter difficulties in expanding into new markets due to stringent regulations and complex entry barriers.
- There might be limitations in terms of global brand recognition compared to larger multinational pharmaceutical companies.
- The company's heavy reliance on a few key suppliers and partners could pose risks to its supply chain management.
Opportunities
- The growing healthcare industry presents opportunities for Cosmos Pharmaceutical Corp to expand its market share and introduce new products.
- Increasing consumer awareness and preference for natural and organic healthcare solutions can be leveraged by the company.
- Exploration of partnerships or acquisitions to enhance research capabilities and gain access to new markets.
- Expansion into emerging markets with rising healthcare needs and less competition can provide substantial growth prospects.
Threats
- The pharmaceutical industry faces constant challenges from evolving regulations and pricing pressures, which can impact Cosmos Pharmaceutical Corp's profitability.
- Intense competition from both established players and emerging startups poses a threat to market share and revenue growth.
- The emergence of counterfeit drugs and regulatory failures can harm the company's reputation and affect consumer confidence.
- Technological advancements and potential disruption in healthcare delivery models could require significant adaptation and investment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.